A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug–Drug Interaction Frequently Observed in Graft versus Host Disease Patients

Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posacon...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerner, Bettina, Aghai-Trommeschlaeger, Fatemeh, Kraus, Sabrina, Grigoleit, Götz Ulrich, Zimmermann, Sebastian, Kurlbaum, Max, Klinker, Hartwig, Isberner, Nora, Scherf-Clavel, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785192/
https://www.ncbi.nlm.nih.gov/pubmed/36559050
http://dx.doi.org/10.3390/pharmaceutics14122556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785192/
https://www.ncbi.nlm.nih.gov/pubmed/36559050
http://dx.doi.org/10.3390/pharmaceutics14122556

Ejemplares similares